<DOC>
	<DOCNO>NCT02239562</DOCNO>
	<brief_summary>The purpose study study safety tolerability synthetic PreImplantation Factor ( sPIF ) female patient autoimmune hepatitis . Autoimmune hepatitis disease patient 's immune system produce inappropriate immune response liver . PreImplantation Factor substance secrete viable fetus pregnancy . PIF apparently initiate maternal tolerance prevent loss/rejection fetus . Synthetic PIF ( sPIF ) successfully translate PIF endogenous property pregnant non-pregnant immune disorder . sPIF find effective preclinical model autoimmunity transplantation ( publish ) . Specifically sPIF protect liver immune attack . In FDA mandate toxicity study ( mouse , dog ) , high-dose sPIF administration 2 week follow 2 week observation period demonstrate high safety profile . Based observation FDA grant Fast Track designation trial . This study evaluate safety , tolerability blood level synthetic version natural compound circulation .</brief_summary>
	<brief_title>sPIF CLINICAL STUDY PROTOCOL FOR AUTOIMMUNE HEPATITIS</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<criteria>Female , age 18 70 year old , nonchild bear potential ( avoid possibility antibody form sPIF could put patient risk future fertility ) Females must either Postmenopausal great two year , Postmenopausal less two year FSH level great &gt; 40mIU/mL Or document surgically sterile ( bilateral tubal ligation , bilateral oophorectomy posthysterectomy ) least three month prior screen evaluation Autoimmune hepatitis document : Pretreatment score ≥15 Or posttreatment score ≥17 International Criteria Diagnosis Autoimmune Hepatitis ( Appendix 2 ) Treatment prednisone and/or oral , immunosuppressive drug ( ) must stabilize least 6 week prior screen study . Stable ALT level fix dose immunosuppressant medication Subjects document relapse completion initial course therapy Permitted concomitant immunosuppressant medication include Azathioprine dose equal to/or le 100 mg per day , Budesonide dose equal to/or le 9 mg per day , Mycophenolate mofetil equal to/or less 3000 mg per day , Prednisone equal to/or le 10 mg per day Ursodeoxycholic acid equal to/or less 1000 mg per day In judgment Investigator , reasonable general health , base review result screen evaluation ( include physical examination , measurement vital sign , 12lead ECG trace collection blood urine routine clinical laboratory test ) , perform 30 day prior Day 1 study . Patients must agree abstain alcohol use participation study protocol . Alanine aminotransferase ( ALT ) level five time upper limit normal ( reference ) range ( ULN ) screen evaluation . Normal renal function determine serum creatinine A female childbearing potential document either surgically sterile ( bilateral tubal ligation , bilateral oophorectomy posthysterectomy least 3 month prior screen evaluation ) postmenopausal ≥ 2 year . Any form chronic liver disease . Decompensated liver disease define basis one follow laboratory parameter screen evaluation : total bilirubin &gt; 1.5 × ULN , prothrombin time &gt; 1.2 × ULN , platelets ≤ 100,000/mm3 , albumin &lt; 3 g/dL OR current prior history clinical hepatic decompensation ( e.g. , ascites , jaundice , encephalopathy variceal hemorrhage ) . Hemoglobin &lt; 11 g/dL screen evaluation . Serological evidence infection HIV upon review medical record . Evidence hepatocellular carcinoma ( i.e. , screen αfetoprotein &gt; 50 ng/mL standard care measure ) . Subjects , history clinically significant oncologic , pulmonary , hepatic , gastrointestinal , renal , cardiovascular , hematologic , metabolic , endocrine , neurologic , immunologic hematologic illness major medical disorder , judgment Investigator , would interfere subject treatment , assessment compliance protocol otherwise preclude participation trial . Have receive therapy potentially hepatotoxic drug within 3 month ( 90 day ) prior Day 1 expect receive therapy study . Patient expect receive change immunosuppressant therapy protocol . Patients may receive chemotherapeutic agent ( e.g. , corticosteroid , immunoglobulin immune cytokinebased therapy ) study medical condition .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sPIF</keyword>
	<keyword>synthetic PreImplantation Factor</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Liver</keyword>
	<keyword>Hepatitis</keyword>
</DOC>